SS18 and synovial sarcoma: This is consistent with the prior finding that expression of the SS18-SSX fusion gene in a noncancerous context (such as mesenchymal progenitor and myoblast cells) can impair normal skeletal muscle development and promote aberrant cell proliferation, contributing to synovial sarcoma-like tumor formation in transgenic mice [21,24,25].